Turning mirror-image oligonucleotides into drugs: the evolution of Spiegelmer therapeutics.
Vater A, Klussmann S. Drug Discov Today. 2015 Jan;20(1):147-55. doi: 10.1016/j.drudis.2014.09.004. Epub 2014 Sep 16.
RNA aptamers and Spiegelmers: synthesis, purification, and post-synthetic PEG conjugation.
Hoffmann S, Hoos J, Klussmann S, Vonhoff S. Curr Protoc Nucleic Acid Chem. 2011 Sep;Chapter 4:Unit 4.46.1-30. doi: 10.1002/0471142700.nc0446s46.
Spiegelmer NOX-E36 for Renal Diseases.
Eulberg, D, Purschke, W, Anders, H-J, Selve, N, Klussmann, S. In: Therapeutic Oligonucleotides, Ed. Jens Kurreck, Biomolecular Sciences Series of the Royal Society of Chemistry (RSC), 2008.
Spiegelmers for Therapeutic Applications – Use of Chiral Principles in Evolutionary Selection Techniques.
Eulberg, D, Jarosch, F, Vonhoff, S, Klussmann, S. In: The Aptamer Handbook, Functional Oligonculeotides and Their Applications, Ed. S. Klussmann, Wiley-VCH Weinheim, 2006.
Enantiomeric Nucleic Acids – Spiegelmers.
Klussmann, S, In: Bioorganic Chemistry II, Eds. C. Schmuck, H. Wennemers, Wiley-VCH, Weinheim, 2004. https://doi.org/10.1002/3527603727.ch3d
Spiegelmers: biostable aptamers.
Eulberg D, Klussmann S. Chembiochem. 2003 Oct 6;4(10):979-83. doi: 10.1002/cbic.200300663.
Toward third-generation aptamers: Spiegelmers and their therapeutic prospects.
Vater A, Klussmann S. Curr Opin Drug Discov Devel. 2003 Mar;6(2):253-61.